According to the agency, Teva communicated that it would have difficulties supplying immediate release formulations of the drug due to manufacturing delays.
Biopharmaceuticals firm Shire will cease manufacture at its plant in Owings Mills, Maryland, US with the loss of 260 jobs in the latest stage of its plan to wind up the in-house production of small molecule drugs.
An approvable letter for Shire's long-lasting formulation of its
best-selling attention deficit and hyperactivity disorder (ADHD)
drug Adderall is not the stumbling block it may appear says the
company.
Shire Pharmaceuticals' plans to buy New River Pharmaceuticals will
eventually affect a contract manufacturing arrangement with Albany
Molecular Research (AMR).
Johnson Matthey has announced a reassuring business update ahead of
its 31 March year-end, suggesting that Adderall is the driving
force behind a recovery in its pharmaceutical materials business.
Shire, Britain's third-biggest drugmaker, has won approval in the
US for Daytrana, a methylphenidate skin patch developed with
Noven's transdermal technology, making it the first non-oral
medication for the treatment of...
Supernus Pharmaceuticals has acquired the drug formulation business
of Shire Laboratories (SLI) in a move that strengthens the
pharmaceutical technologies and services. The company will make use
of the patents to improve its own portfolio...